公开(公告)号：US20120213794A1

公开(公告)日：2012-08-23

申请号：US13503729

申请日：2010-10-29

Applicant: Peter Peizhi Luo ,  Kevin Caili Wangr ,  Pingyu Zhong ,  Mark Hsieh ,  Yan Li ,  Xinwei Wang ,  Feng Dong ,  Andrei Golosov ,  Yan Ni ,  Weirong Wang ,  Laurence B. Peterson ,  Rose Cubbon ,  Sujata Sharma ,  Jon Condra ,  Jun Lu ,  Gopalakrishnan Parthasarathy ,  Stephen Soisson ,  Noel Byrne

Inventor： Peter Peizhi Luo ,  Kevin Caili Wangr ,  Pingyu Zhong ,  Mark Hsieh ,  Yan Li ,  Xinwei Wang ,  Feng Dong ,  Andrei Golosov ,  Yan Ni ,  Weirong Wang ,  Laurence B. Peterson ,  Rose Cubbon ,  Sujata Sharma ,  Jon Condra ,  Jun Lu ,  Gopalakrishnan Parthasarathy ,  Stephen Soisson ,  Noel Byrne

IPC: A61K39/395 ,  C12N15/13 ,  C12P21/02 ,  A61P3/06 ,  C12N5/10 ,  C12N1/19 ,  C12N1/21 ,  C07K16/40 ,  C12N15/63

CPC classification number: C07K16/40 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/94 ,  C07K2319/00

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract translation: 公开了人前体蛋白转化酶枯草杆菌蛋白酶-Kexin 9型（“PCSK9”）的拮抗剂。 所公开的拮抗剂在抑制PCSK9功能方面是有效的，因此，呈现用于治疗与PCSK9活性相关的病症的所需拮抗剂。 本发明还公开了编码所述拮抗剂，载体，宿主细胞和包含拮抗剂的组合物的核酸。 还公开了制备PCSK9特异性拮抗剂的方法以及使用拮抗剂抑制或拮抗PCSK9功能的方法，并形成了本公开的重要的附加方面。

公开(公告)号：US20150030594A1

公开(公告)日：2015-01-29

申请号：US14336290

申请日：2014-07-21

Applicant: Jun YUAN ,  Frederic ZECRI ,  Philipp GROSCHE ,  Hongjuan ZHAO ,  Andrei GOLOSOV ,  Kayo YASOSHIMA ,  David Thomas PARKER ,  Eric PETERS ,  Aimee Richardson USERA ,  Shari Lynn CAPLAN ,  Aaron KANTER ,  Changgang LOU ,  Carla Guimaraes

Inventor： Jun YUAN ,  Frederic ZECRI ,  Philipp GROSCHE ,  Hongjuan ZHAO ,  Andrei GOLOSOV ,  Kayo YASOSHIMA ,  David Thomas PARKER ,  Eric PETERS ,  Aimee Richardson USERA ,  Shari Lynn CAPLAN ,  Aaron KANTER ,  Changgang LOU ,  Carla Guimaraes

IPC: C07K7/08 ,  A61K45/06 ,  C07K14/47 ,  C07K16/00 ,  A61K39/395 ,  A61K47/48 ,  A61K38/10

CPC classification number: A61K38/10 ,  A61K38/00 ,  A61K45/06 ,  A61K47/542 ,  A61K47/643 ,  A61K47/68 ,  A61K47/6811 ,  C07K14/47 ,  C07K14/765 ,  C07K2319/30 ,  C07K2319/31

Abstract: The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I′ (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract translation: 本发明提供包含式I'（SEQ ID NO：1）的合成多肽的生物缀合物或其酰胺，其酯或其盐，其中X 1，X 2，X 3，X 4，X 5，X 6，X 7，X 8，X 9 ，X10，X11，X12和X13在本文中定义并且半衰期延长部分，其中肽和半衰期延长部分任选地经由连接体共价连接或融合。 多肽是APJ受体的激动剂。 本发明还涉及本发明的生物缀合物的制备方法及其治疗用途，例如治疗或预防急性失代偿性心力衰竭（ADHF），慢性心力衰竭，肺动脉高压，心房颤动，布鲁加达综合征，室性心动过速，动脉粥样硬化 ，高血压，再狭窄，缺血性心血管疾病，心肌病，心脏纤维化，心律失常，保水，糖尿病（包括妊娠糖尿病），肥胖，外周动脉疾病，脑血管意外，短暂性脑缺血发作，创伤性脑损伤，肌萎缩性侧索硬化，烧伤（ 包括晒伤）和先兆子痫。 本发明还提供药理活性剂和药物组合物的组合。

公开(公告)号：US08877900B2

公开(公告)日：2014-11-04

申请号：US13503729

申请日：2010-10-29

Applicant: Peter Peizhi Luo ,  Kevin Caili Wangr ,  Pingyu Zhong ,  Mark Hsieh ,  Yan Li ,  Xinwei Wang ,  Feng Dong ,  Andrei Golosov ,  Yan Ni ,  Weirong Wang ,  Laurence B. Peterson ,  Rose Cubbon ,  Sujata Sharma ,  Jon Condra ,  Jun Lu ,  Gopalakrishnan Parthasarathy ,  Stephen Soisson ,  Noel Byrne

Inventor： Peter Peizhi Luo ,  Kevin Caili Wangr ,  Pingyu Zhong ,  Mark Hsieh ,  Yan Li ,  Xinwei Wang ,  Feng Dong ,  Andrei Golosov ,  Yan Ni ,  Weirong Wang ,  Laurence B. Peterson ,  Rose Cubbon ,  Sujata Sharma ,  Jon Condra ,  Jun Lu ,  Gopalakrishnan Parthasarathy ,  Stephen Soisson ,  Noel Byrne

IPC: C07K16/40 ,  C07K16/00 ,  A61K39/395

CPC classification number: C07K16/40 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/94 ,  C07K2319/00

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract translation: 公开了人前体蛋白转化酶枯草杆菌蛋白酶-Kexin 9型（“PCSK9”）的拮抗剂。 所公开的拮抗剂在抑制PCSK9功能方面是有效的，因此，呈现用于治疗与PCSK9活性相关的病症的所需拮抗剂。 本发明还公开了编码所述拮抗剂，载体，宿主细胞和包含拮抗剂的组合物的核酸。 还公开了制备PCSK9特异性拮抗剂的方法以及使用拮抗剂抑制或拮抗PCSK9功能的方法，并形成了本公开的重要的附加方面。

公开(公告)号：US09067971B2

公开(公告)日：2015-06-30

申请号：US14165680

申请日：2014-01-28

Applicant: Frederic Zecri ,  Andrei Golosov ,  Philippr Grosche ,  Hongjuan Zhao ,  Qi-Ying Hu ,  Hidetomo Imase

Inventor： Frederic Zecri ,  Andrei Golosov ,  Philippr Grosche ,  Hongjuan Zhao ,  Qi-Ying Hu ,  Hidetomo Imase

IPC: C07K7/08 ,  C07K7/56 ,  C07K7/60 ,  A61K38/00

CPC classification number: A61M16/0816 ,  A61K38/00 ,  A61K38/10 ,  A61M16/0066 ,  A61M16/201 ,  A61M2016/0027 ,  A61M2016/003 ,  A61M2205/35 ,  A61M2205/502 ,  C07K7/08 ,  C07K7/56 ,  C07K7/60

Abstract: The invention provides a synthetic polypeptide of Formula I′: or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract translation: 本发明提供式I'的合成多肽：或其酰胺，酯或其盐，其中X1，X2，X3，X4，X5，X6，X7，X8，X9，X10，X11，X12和X13被定义 这里。 多肽是APJ受体的激动剂。 本发明还涉及制备本发明多肽的方法及其治疗用途，例如治疗或预防急性失代偿性心力衰竭（ADHF），慢性心力衰竭，肺动脉高压，心房颤动，Brugada综合征，室性心动过速，动脉粥样硬化 ，高血压，再狭窄，缺血性心血管疾病，心肌病，心脏纤维化，心律失常，保水，糖尿病（包括妊娠糖尿病），肥胖，外周动脉疾病，脑血管意外，短暂性脑缺血发作，创伤性脑损伤，肌萎缩性侧索硬化，烧伤（ 包括晒伤）和先兆子痫。 本发明还提供药理活性剂和药物组合物的组合。

公开(公告)号：US08673848B2

公开(公告)日：2014-03-18

申请号：US13747621

申请日：2013-01-23

Applicant: Frédéric Zecri ,  Andrei Golosov ,  Philipp Grosche ,  Kayo Yasoshima ,  Hongjuan Zhao ,  Qi-Ying Hu ,  Hidetomo Imase ,  David Thomas Parker

Inventor： Frédéric Zecri ,  Andrei Golosov ,  Philipp Grosche ,  Kayo Yasoshima ,  Hongjuan Zhao ,  Qi-Ying Hu ,  Hidetomo Imase ,  David Thomas Parker

IPC: C07K7/08 ,  C07K7/60 ,  C07K7/56

CPC classification number: A61M16/0816 ,  A61K38/00 ,  A61K38/10 ,  A61M16/0066 ,  A61M16/201 ,  A61M2016/0027 ,  A61M2016/003 ,  A61M2205/35 ,  A61M2205/502 ,  C07K7/08 ,  C07K7/56 ,  C07K7/60

Abstract: The invention provides a synthetic polypeptide of Formula I′: or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract translation: 本发明提供式I'的合成多肽：或其酰胺，酯或其盐，其中X1，X2，X3，X4，X5，X6，X7，X8，X9，X10，X11，X12和X13被定义 这里。 多肽是APJ受体的激动剂。 本发明还涉及制备本发明多肽的方法及其治疗用途，例如治疗或预防急性失代偿性心力衰竭（ADHF），慢性心力衰竭，肺动脉高压，心房颤动，Brugada综合征，室性心动过速，动脉粥样硬化 ，高血压，再狭窄，缺血性心血管疾病，心肌病，心脏纤维化，心律失常，保水，糖尿病（包括妊娠糖尿病），肥胖，外周动脉疾病，脑血管意外，短暂性脑缺血发作，创伤性脑损伤，肌萎缩性侧索硬化，烧伤（ 包括晒伤）和先兆子痫。 本发明还提供药理活性剂和药物组合物的组合。

公开(公告)号：US20120231005A1

公开(公告)日：2012-09-13

申请号：US13503726

申请日：2010-10-29

Applicant: Peter Peizhi Luo ,  Kevin Caili Wang ,  Pingyu Zhong ,  Mark Hsieh ,  Yan Li ,  Xinwei Wang ,  Feng Dong ,  Andrei Golosov ,  Yan Ni ,  Weirong Wang ,  Laurence B. Peterson ,  Rose Cubbon

Inventor： Peter Peizhi Luo ,  Kevin Caili Wang ,  Pingyu Zhong ,  Mark Hsieh ,  Yan Li ,  Xinwei Wang ,  Feng Dong ,  Andrei Golosov ,  Yan Ni ,  Weirong Wang ,  Laurence B. Peterson ,  Rose Cubbon

IPC: C07K16/40 ,  C12N9/99 ,  C12N1/21 ,  C12N15/13 ,  C12N5/10 ,  C12P21/02 ,  A61K39/395 ,  C12N15/63 ,  C12N1/19

CPC classification number: C07K16/40 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract translation: 公开了人前体蛋白转化酶枯草杆菌蛋白酶-Kexin 9型（“PCSK9”）的拮抗剂。 所公开的拮抗剂在抑制PCSK9功能方面是有效的，因此，呈现用于治疗与PCSK9活性相关的病症的所需拮抗剂。 本发明还公开了编码所述拮抗剂，载体，宿主细胞和包含拮抗剂的组合物的核酸。 还公开了制备PCSK9特异性拮抗剂的方法以及使用拮抗剂抑制或拮抗PCSK9功能的方法，并形成了本公开的重要的附加方面。

公开(公告)号：US20160297854A1

公开(公告)日：2016-10-13

申请号：US15186025

申请日：2016-06-17

Applicant: Joy GHOSH ,  Michael ROGUSKA ,  Andrew Anh NGUYEN ,  Thomas PIETZONKA ,  Matthias MACHACEK ,  Andrei GOLOSOV

Inventor： Joy GHOSH ,  Michael ROGUSKA ,  Andrew Anh NGUYEN ,  Thomas PIETZONKA ,  Matthias MACHACEK ,  Andrei GOLOSOV

IPC: C07K14/00 ,  A61K31/713 ,  A61K47/48 ,  C07K16/22 ,  C12N15/115

CPC classification number: C07K14/00 ,  A61K31/713 ,  A61K38/00 ,  A61K39/3955 ,  A61K47/42 ,  A61K47/64 ,  C07K14/4718 ,  C07K16/22 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/20 ,  C07K2319/31 ,  C07K2319/33 ,  C12N15/115 ,  C12N2310/16 ,  C12N2310/3513 ,  C12N2320/32

Abstract: The invention relates, in part, to compositions and methods that utilize a peptide tag that binds to hemagglutanin (HA). The HA tag can be linked to a molecule such as a protein or nucleic acid which, when administered to the eye, results in an increase in ocular half-life and/or mean residence time, and or a decrease in ocular clearance of the protein or nucleic acid. The invention also encompasses methods for treating ocular disease, including retinal vascular disease, by administering a protein or nucleic acid linked to an HA peptide tag.

Abstract translation: 本发明部分地涉及利用结合血凝素（HA）的肽标签的组合物和方法。 HA标签可以连接到分子，例如蛋白质或核酸，当被施用于眼睛时，导致眼半衰期和/或平均停留时间的增加和/或蛋白质的眼清除率的降低 或核酸。 本发明还包括通过施用与HA肽标签连接的蛋白质或核酸来治疗眼部疾病（包括视网膜血管疾病）的方法。

公开(公告)号：US08802827B2

公开(公告)日：2014-08-12

申请号：US13503726

申请日：2010-10-29

Applicant: Peter Peizhi Luo ,  Kevin Caili Wang ,  Pingyu Zhong ,  Mark Hsieh ,  Yan Li ,  Xinwei Wang ,  Feng Dong ,  Andrei Golosov ,  Yan Ni ,  Weirong Wang ,  Laurence B. Peterson ,  Rose Cubbon

Inventor： Peter Peizhi Luo ,  Kevin Caili Wang ,  Pingyu Zhong ,  Mark Hsieh ,  Yan Li ,  Xinwei Wang ,  Feng Dong ,  Andrei Golosov ,  Yan Ni ,  Weirong Wang ,  Laurence B. Peterson ,  Rose Cubbon

IPC: C07K16/40 ,  C07K16/00 ,  A61K39/395

CPC classification number: C07K16/40 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract translation: 公开了人前体蛋白转化酶枯草杆菌蛋白酶-Kexin 9型（“PCSK9”）的拮抗剂。 所公开的拮抗剂在抑制PCSK9功能方面是有效的，因此，呈现用于治疗与PCSK9活性相关的病症的所需拮抗剂。 本发明还公开了编码所述拮抗剂，载体，宿主细胞和包含拮抗剂的组合物的核酸。 还公开了制备PCSK9特异性拮抗剂的方法以及使用拮抗剂抑制或拮抗PCSK9功能的方法，并形成了本公开的重要的附加方面。

公开(公告)号：US20130196899A1

公开(公告)日：2013-08-01

申请号：US13747621

申请日：2013-01-23

Applicant: Frédéric ZECRI ,  Andrei GOLOSOV ,  Philipp GROSCHE ,  Kayo YASOSHIMA ,  Hongjuan ZHAO ,  Qi-Ying HU ,  Hidetomo IMASE ,  David Thomas PARKER

Inventor： Frédéric ZECRI ,  Andrei GOLOSOV ,  Philipp GROSCHE ,  Kayo YASOSHIMA ,  Hongjuan ZHAO ,  Qi-Ying HU ,  Hidetomo IMASE ,  David Thomas PARKER

IPC: C07K7/08 ,  C07K7/60 ,  C07K7/56

CPC classification number: A61M16/0816 ,  A61K38/00 ,  A61K38/10 ,  A61M16/0066 ,  A61M16/201 ,  A61M2016/0027 ,  A61M2016/003 ,  A61M2205/35 ,  A61M2205/502 ,  C07K7/08 ,  C07K7/56 ,  C07K7/60

Abstract: The invention provides a synthetic polypeptide of Formula I′: or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract translation: 本发明提供式I'的合成多肽：或其酰胺，酯或其盐，其中X1，X2，X3，X4，X5，X6，X7，X8，X9，X10，X11，X12和X13被定义 这里。 多肽是APJ受体的激动剂。 本发明还涉及制备本发明多肽的方法及其治疗用途，例如治疗或预防急性失代偿性心力衰竭（ADHF），慢性心力衰竭，肺动脉高压，心房颤动，Brugada综合征，室性心动过速，动脉粥样硬化 ，高血压，再狭窄，缺血性心血管疾病，心肌病，心脏纤维化，心律失常，保水，糖尿病（包括妊娠糖尿病），肥胖，外周动脉疾病，脑血管意外，短暂性脑缺血发作，创伤性脑损伤，肌萎缩性侧索硬化，烧伤（ 包括晒伤）和先兆子痫。 本发明还提供药理活性剂和药物组合物的组合。

公开(公告)号：US20230071283A1

公开(公告)日：2023-03-09

申请号：US16093758

申请日：2017-04-14

Applicant: Andrei Golosov ,  Carla Patricia Pinto Guimaraes ,  Gregory Motz ,  Michael C. Milone ,  Christoph T. Ellebrecht ,  Aimee S. Payne ,  Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Andrei Golosov ,  Carla Patricia Pinto Guimaraes ,  Gregory Motz ,  Michael C. Milone ,  Christoph T. Ellebrecht ,  Aimee S. Payne

IPC: C07K14/725

Abstract: Provided herein are fusion proteins including two protein domains separated by a heterologous protease cleavage site, wherein a first of the protein domains is a conditional expression domain. Thus, the fusion proteins comprise three essential elements: a conditional expression domain, a domain containing the protein of interest, and a protease cleavage domain separating the two. Also provided herein are methods for treating autoantibody and alloantibody-mediated diseases or conditions in a subject by targeting B cells with anti-B cell modified T cells. In one embodiment, a chimeric antigen receptor (CAR) modified T cell is selectively ablated in a subject after adoptive transfer. Pharmaceutical compositions comprising the temporally regulated CAR modified T cell are also described herein.